Strides Pharma Science Ltd

Merger & Restructuring

Strides Pharma Science Merger & Restructuring Worth ₹100 Cr

Strides Pharma is selling a majority stake in subsidiary Pivot Path for ₹100 Crore. The buyer consortium includes Ascent Capital and Vintage Classic.

Value

₹100.0 Cr

Execution

Completion expected by June 30, 2026

Merger & Restructuring

Strides Pharma Science Merger & Restructuring Worth ₹230 Cr

Strides Pharma Science announced a strategic investment in subsidiary Pivot Path by Ascent Capital. The deal values Pivot Path at Rs. 230 Crore post-money.

Value

₹230.0 Cr

Merger & Restructuring

Strides Pharma Science Merger & Restructuring

Strides Pharma Science announced that the demerger scheme between Arco Lab and Pivot Path became effective on June 1, 2026. This follows final NCLT and ROC approvals.

Merger & Restructuring

Strides Pharma Science Merger & Restructuring

NCLT Bengaluru Bench approved Strides Pharma's scheme to demerge Arco Lab's life sciences and digital units into Pivot Path. The restructuring aims to optimize business segments.